Liberty Health Sciences Ranks # 2 In Flower Sales In Florida
TORONTO, July 24, 2019 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high quality cannabis, announced today that it has the second highest sales of smokable marijuana in the state of Florida with 16 dispensaries open. Liberty was one of the first companies in the state to provide smokable medical marijuana in all of its dispensaries when bill (SB 182) was signed into law on March 8, 2019 revoking a ban on smoking medical marijuana.
Flower sales of Liberty and Papa’s Herb brands is the driving factor of the significant market success for this growing category and the Company continues to cultivate brand recognition and attract a constant stream of new patients.
Senate Bill 182 permits qualified patients to receive up to 2.5 ounces of whole flower (smokable) cannabis every 35 days. As of July 19, 2019, the Office of Medical Marijuana Use (OMMU) reports there are 246,079 qualified patients and 2,386 physicians in Florida.
With the passing of Amendment 2 and the subsequent Senate Bill 8A in 2017, Florida legalized medical cannabis for 10 qualifying conditions: cancer, epilepsy, glaucoma, HIV, AIDS, Post Traumatic Stress Disorder (PTSD), Amyotrophic Lateral Sclerosis (ALS), Crohn’s Disease, Parkinson’s Disease, and Multiple Sclerosis (MS), as well as “medical conditions of the same kind or class as or comparable to the above qualifying conditions,” such as Generalized Anxiety Disorder.
“Our outstanding results are directly driven by the strategy that we have been implementing,” said Victor Mancebo, Interim Chief Executive Officer of Liberty. “This is a very proud moment for the Liberty team as we outranked other MMTC’s in Florida. Most importantly, we continue to provide all Florida patients the medicine that they are seeking. As we aggressively continue to grow our footprint and product portfolio, we expect to amplify our results and progressively increase the offerings for our patients.”
Liberty Health Sciences is quickly becoming a leading cultivator and distributor of premium cannabis products through low-cost production techniques and high-end dispensary design. The Company continues to successfully expand its house flower brand of products and prides itself in offering access to the best brands in any category, including PAX, Mary’s Medicinals, Pretty Pistil, and Papa’s Herb to name a few.
Liberty currently operates 16 dispensaries across Florida, with the Boca Raton location celebrating its opening on July 22, where it serves a population of approximately 100,000. Next month Liberty plans to open three new dispensaries in Panama City, Pensacola, and Orlando, joining the list of store locations listed below:
• Dania Beach
• North Miami
• Port St. Lucie
• Palm Harbor
• St. Petersburg
• Orange Park
• Tampa (Hyde Park)
• Winter Haven
• Merritt Island
• Cape Coral
• Boca Raton
• Bonita Springs
Patients may place an order online at www.libertyhealthsciences.com for in-store pick-up or free delivery. Liberty also offers patients free statewide delivery.
About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale. Liberty’s measured approach to expansion opportunities is focused on maximizing returns to shareholders, while keeping consumers’ well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company’s production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries and the expansion of its greenhouse space, and the Company’s future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United Statesgenerally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Liberty Health Sciences Inc.
Liberty Health Sciences Ranks # 2 In Flower Sales In Florida
About Cannin: Your Marijuana Stock Experts
Cannin is your #1 trusted resource for marijuana and hemp stock investment opportunities. Our global team of experts evaluates all emerging marijuana and hemp stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best marijuana and hemp stock investments for 2020.
Use Cannin as your resource for:
- Cannabis and hemp investing news
- Featured cannabis and hemp company analysis
- Comprehensive cannabis and hemp stock reports
Is it too late to invest in marijuana or hemp stocks? No! This is the perfect time to invest.
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in marijuana and hemp stocks is now. Are you looking to buy stock in hemp companies or marijuana companies for 2020? Interested in emerging penny hemp stock companies? Looking for the best Canadian marijuana stocks to invest in? We can help.
Predict price movements of marijuana and hemp stocks several hours in advance with our proprietary algorithmic stock trading software.
- +25% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
We’re so confident you’ll love our signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best marijuana stocks – we’ll show you how at cannin.com
Can we start writing exclusively about Hemp-Only companies? These include the following: Charlotte’s Web, GW Pharma, CV Sciences, Canopy Growth, Elixinol, Organigram, GrowLife, Emerald Health, Neptune, Global Hemp Group. Also, please see the attached report with additional hemp only companies with analysis. It’s from last year so the data is not current but worth a look.
Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Hemp stocks